Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT30FV
|
|||
| Drug Name |
VNRX-5133
|
|||
| Synonyms |
Taniborbactam; UNII-8IGQ156Z07; 8IGQ156Z07; 1613267-49-4; (3R)-3-[[2-[4-(2-aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid; (3~{R})-3-[2-[4-(2-azanylethylamino)cyclohexyl]ethanoylamino]-2-oxidanyl-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid; Taniborbactam [INN]; Taniborbactam [USAN]; Taniborbactam (USAN/INN); VNRX5133; CHEMBL4463697; CHEMBL4584705; CHEMBL4594290; SCHEMBL15778142; SCHEMBL15778144; SCHEMBL15779391; GTPL10774; WHO 10817; HY-109124; CS-0078360; D11718; (3R)-3-(((trans-4-((2-Aminoethyl)amino)cyclohexyl)acetyl)amino)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid; (R)-3-(2-((1S,4R)-rel-4-((2-Aminoethyl)amino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid; (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid; 2H-1,2-Benzoxaborin-8-carboxylic acid, 3-((2-(trans-4-((2-aminoethyl)amino)cyclohexyl)acetyl)amino)-3,4-dihydro-2-hydroxy-, (3R)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 1 | [1] | |
| Company |
VenatoRx Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C19H28BN3O5
|
|||
| Canonical SMILES |
B1(C(CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O
|
|||
| InChI |
1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
|
|||
| InChIKey |
PFZUWUXKQPRWAL-PXCJXSSVSA-N
|
|||
| CAS Number |
CAS 1613267-49-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Beta-lactamase (Stap-coc blaZ) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02955459) VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.